PTEN proved to be a vital factor for promoting the response to MAPK inhibitors in myeloid leukemia, as PTEN regulates EGR1 expression and contributes to the cytokine sensitivity when treated with MAPK inhibitors [38]. This evidence concerns the gene PTEN and myeloid leukemia.